

表2-2 内分泌かく乱化学物質と子宮体がんに関する症例対照研究

| 地域・対象者数 | 化合物 | 血清レベルの比較 | | | カテゴリー毎のオッズ比 | | | | |
|---------------------------|---|----------|------------------|------|-------------|--------------|--------------|--------------|---------|
| | | 症例 | 対照 | P値 | 1(低) | 2 | 3 | 4(高) | P trend |
| Sturgeon, 1998 | | | | | | | | | |
| 米国5地域 症例90 住民対照90 | p,p'-DDE o,p'-DDT p,p'-DDT Total PCBs Estrogenic PCB ¹⁾ Antiestrogenic PCB ²⁾ Enzyme-inducing PCB ³⁾ Beta-HCH Dieldrin HCB Heptachlor epoxide Oxychlordane Trans-nonachlor | | 中央値 (ng/g lipid) | | | | | | |
| | | 1417 | 1358 | 0.58 | 1.0 | 0.5(0.2-1.2) | 1.0(0.4-2.5) | 0.7(0.2-2.0) | |
| | | 11 | 19 | 0.09 | 1.0 | 0.9(0.4-2.1) | 0.5(0.1-1.9) | | |
| | | 69 | 0 | 0.03 | 1.0 | 0.6(0.2-1.6) | 1.8(0.7-4.4) | | |
| | | 302 | 350 | 0.48 | 1.0 | 1.1(0.4-3.0) | 0.7(0.3-2.0) | 0.9(0.4-2.5) | |
| | | 1 | 1 | 0.84 | 1.0 | 1.1(0.5-2.4) | 1.3(0.5-3.2) | | |
| | | 166 | 176 | 0.86 | 1.0 | 1.2(0.5-3.2) | 1.2(0.4-3.0) | 1.1(0.4-3.1) | |
| | | 81 | 102 | 0.08 | 1.0 | 0.6(0.2-1.5) | 0.7(0.3-1.8) | 0.6(0.2-1.6) | |
| | | 38 | 35 | 0.37 | 1.0 | 0.8(0.3-2.3) | 0.5(0.1-1.4) | 0.9(0.3-2.6) | |
| | | 8 | 0 | 0.03 | 1.0 | 2.1(0.9-4.2) | 1.9(0.7-4.8) | | |
| | | 43 | 45 | 0.32 | 1.0 | 0.6(0.2-1.8) | 0.5(0.2-1.7) | 0.8(0.2-2.6) | |
| | | 0 | 0 | 0.08 | 1.0 | 0.6(0.3-4.6) | 1.2(0.5-3.0) | | |
| | | 0 | 1 | 0.56 | 1.0 | 0.6(0.2-1.5) | 0.7(0.3-1.9) | | |
| | | 2 | 10 | 0.54 | 1.0 | 0.6(0.2-2.0) | 1.0(0.4-2.7) | | |
| Weiderpass, 2000 | | | | | | | | | |
| スエーデン 症例154 住民対照205 | p,p'-DDT o,p'-DDT p,p'-DDE p,p'-DDD HCB Alfa-HCH Beta-HCH Gamma-HCH Oxychlordane Trans-nonachlor PCB28 PCB52 PCB101 PCB105 PCB118 PCB138 PCB153 | | 中央値 (ng/g lipid) | | | | | | |
| | | 17.8 | 13.9 | 0.01 | 1.0 | 1.1(0.6-2.2) | 0.8(0.4-1.6) | 1.1(0.5-2.1) | 0.95 |
| | | 2 | 2 | 0.37 | | | | | |
| | | 582.5 | 497 | 0.04 | 1.0 | 0.9(0.5-1.8) | 1.1(0.6-2.0) | 1.0(0.6-2.0) | 0.78 |
| | | 2 | 2 | 0.84 | | | | | |
| | | 66.8 | 64.9 | 0.08 | 1.0 | 1.2(0.6-2.2) | 1.0(0.5-1.9) | 1.0(0.5-1.9) | 0.76 |
| | | 1 | 1 | 0.81 | | | | | |
| | | 57.8 | 51.1 | 0.02 | 1.0 | 0.8(0.4-1.5) | 1.0(0.5-2.0) | 0.9(0.5-1.9) | 0.87 |
| | | 1 | 1 | 0.17 | | | | | |
| | | 14.4 | 12.8 | 0.01 | 1.0 | 1.1(0.6-2.2) | 1.0(0.5-2.0) | 1.4(0.7-2.8) | 0.33 |
| | | 25.0 | 22.5 | 0.06 | 1.0 | 1.2(0.6-2.3) | 1.3(0.7-2.7) | 1.2(0.6-2.5) | 0.56 |
| | | 3.8 | 3.0 | 0.02 | | | | | |
| | | 1 | 1 | 0.45 | | | | | |
| | | 1 | 1 | 0.10 | | | | | |
| | | 6.1 | 5.6 | 0.14 | 1.0 | 1.2(0.6-2.3) | 1.0(0.5-1.8) | 0.8(0.4-1.6) | 0.42 |
| | | 50.2 | 43.0 | 0.01 | 1.0 | 0.6(0.8-3.0) | 1.2(0.6-2.4) | 1.4(0.7-2.8) | 0.58 |
| | | 107.5 | 101 | 0.30 | 1.0 | 0.8(0.4-1.6) | 1.2(0.6-2.2) | 0.9(0.5-1.7) | 0.95 |
| | | 226.5 | 223 | 0.74 | 1.0 | 0.9(0.5-1.7) | 1.2(0.6-2.2) | 0.9(0.5-1.7) | 0.94 |

| | | | | | | | |
|--|------|------|------|------------------|--------------|--------------|------|
| PCB156 | 17.4 | 18.1 | 0.75 | 1.0 1.6(0.8-2.9) | 1.4(0.7-2.6) | 1.0(0.5-2.0) | 0.90 |
| PCB167 | 9.3 | 8.7 | 0.06 | 1.0 2.0(1.0-3.9) | 1.4(0.7-2.9) | 1.9(0.9-3.9) | 0.24 |
| PCB180 | 147 | 152 | 0.80 | 1.0 1.1(0.6-2.0) | 1.1(0.6-2.2) | 1.2(0.6-2.2) | 0.67 |
| All PCBs ⁴⁾ | | | | 1.0 1.1(0.6-2.2) | 1.1(0.6-2.2) | 1.2(0.6-2.2) | 0.72 |
| Estrogenic compounds ⁵⁾ | | | | 1.0 1.1(0.6-2.1) | 0.9(0.4-1.7) | 1.1(0.6-2.2) | 0.90 |
| Antiestrogenic compounds ⁶⁾ | | | | 1.0 1.7(0.9-3.3) | 1.4(0.7-2.8) | 1.5(0.7-3.0) | 0.48 |
| Compounds with no known hormonal effect ⁷⁾ | | | | 1.0 1.2(0.6-2.2) | 1.4(0.7-2.7) | 1.3(0.7-2.4) | 0.39 |

1) PCB 52, 101, 187, 177, 201.

2) PCB 66, 74, 105, 118, 156, 138.

3) PCB 99, 153, 203, 183.

4) PCB 28, 52, 101, 105, 118, 138, 153, 156, 167, 180.

5) o,p'-DDT, p,p'-DDT, p,p'-DDD, beta-HCH, gamma-HCH, trans-nonachlor, oxychlordane, PCB 28, 52, 101, 153.

6) PCB 105, 118, 156, 167.

7) p,p'-DDE, alfa-HCH, HCB, PCB 138, 180.